T-20 (Enfuvirtide, Fuzeon): Research
- People Who Use Fuzeon May Be at 34 Percent Higher Risk for Pneumonia (May 2, 2011)
From Project Inform
On TheBodyPRO.com
- Needle-Free Mode of T-20 Dosing Looks Highly Satisfactory for Patients (August 28, 2006)
From aidsmap.com
- HIV JournalView: Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006 (July 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Fuzeon Recommended for CD4 Counts Over 100, Viral Loads Below 100,000 (October 2004)
Quick recap of recommendations published in the journal AIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
- HIV JournalView: Long-Term Resistance Patterns on Enfuvirtide (September 2004)
From TheBodyPRO.com
- Enfuvirtide Benefits Persist for at Least 2 Years (July 12, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Global Guidelines Published on Enfuvirtide Use (May 18, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Drug Development News: Trimeris (May/June 2004)
Efforts are under way to improve the delivery method of T-20.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Enfuvirtide Safe and Effective for Adolescents (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Enfuvirtide (September 2003)
2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Food and Drug Administration Approves First in Class of AIDS Drugs (March 14, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (March 13, 2003)
Results published early from the TORO-1 study investigating T-20 in treatment-experienced patients.
To read PDF, click here.
In New England Journal of Medicine
- New AIDS Drug May Help Expand Treatable Groups (March 2003)
In Body Positive, from Body Positive
|
Advertisement
|
Email
Glossary
